AbbVie’s Aquipta Receives EC Approval for Acute Migraine Treatment

Shots: The EC has approved AbbVie's Aquipta (atogepant) for the acute treatment of migraine in adults with or without aura, to be taken as needed Approval was supported by the P-III (ECLIPSE) trial data assessing Aquipta/Qulipta (60mg, PO) vs PBO as an acute treatment of migraine with or without aura in 1,328 adults (18-75yrs.) Trial met…

ByRidhi RastogiJune 2, 2026

NEWS

Rallybio to Merge with Avenzo Therapeutics to Advance Next-Generation Oncology Therapies

Shots: Rallybio has entered into a definitive agreement to acquire Avenzo through a merger transaction, after which the combined company will operate under the name Avenzo Therapeutics & is expected to trade on Nasdaq under the ticker symbol "AVZO" As per the deal, Avenzo shareholders will receive newly issued Rallybio shares based on the companies’…

ByRidhi RastogiJune 2, 2026

NEWS

Amgen Reports the EC Approval of Imdylltra to Treat ES-SCLC

Shots: The EC has approved Imdylltra (tarlatamab) as a monotx. to treat adults with extensive-stage small cell lung cancer (ES-SCLC) who require systemic therapy following disease progression on or after 1L treatment with Pt-based CT Approval was based on the P-III (DeLLphi-304) trial assessing Imdelltra vs SoC CT (topotecan globally excl. Japan; lurbinectedin in the…

ByRidhi RastogiJune 2, 2026

NEWS

Servier to Acquire Edgewise Therapeutics’ Muscular Dystrophy Business for ~$2.65B

Shots: Servier has entered into an agreement with Edgewise Therapeutics to acquire its muscular dystrophy business, supporting Servier’s strategic ambition in rare neurology As per the deal, Servier will acquire the muscular dystrophy business for ~$2.65B, incl. $1.55B upfront and ~$1.1B in regulatory & commercial milestone payments; closing is expected in Q3’26 The acquisition adds Edgewise’s…

ByRidhi RastogiJune 2, 2026

NEWS

Haisco Enters ~$3.05B License and Research Collaboration with Lilly to Develop Novel Medicines Across Multiple Therapeutic Areas

Shots: Haisco Pharmaceutical has entered into a licensing & research collaboration with Eli Lilly to develop novel medicines across multiple therapeutic areas As per the deal, Haisco will be responsible for the discovery & identification of ~5 target programs, while Lilly will lead IND-enabling studies, clinical development, & commercialization Lilly will gain exclusive global rights…

ByRidhi RastogiJune 1, 2026

NEWS

Revolution Medicines Highlights P-III (RASolute 302) Trial Results on Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer

Shots: As of Feb 10, 2026 (mFU: 8.5mos.), the P-III trial assessing daraxonrasib (300mg, QD, PO; n=248) vs CT (n=252) in previously treated metastatic PDAC, regardless of RAS mutation, met all 1 & key 2EPs, showing benefits in both the RAS G12 mutant (daraxonrasib n=228; CT n=231) & overall population Daraxonrasib improved OS by 60% in…

ByRidhi RastogiJune 1, 2026

NEWS

Agios Pharmaceuticals Licenses Cevidoplenib from Oscotec in a ~$165M Deal

Shots: Oscotec has granted Agios exclusive global rights to cevidoplenib (PO), a spleen tyrosine kinase inhibitor, across all indications, incl. immune thrombocytopenia (ITP) As per the deal, Agios will assume full development & commercialization costs, while Oscotec will receive $25M upfront, ~$140M in development & regulatory milestones across ~3 indications in the US & EU,…

ByRidhi RastogiJune 1, 2026

NEWS

NeuroPace Receives the US FDA Approval for ECoG Assistant to Advance AI-Driven Epilepsy Care

Shots: The US FDA has approved ECoG Assistant, an AI-powered clinician tool designed to support epilepsy management using data from the RNS System, with NeuroPace debuting the tool at ASSFN’26 ECoG Assistant was developed using 124,450 epileptologist-labeled intracranial EEG records & identifies ECoGs of Interest, enabling clinicians to review long-term EEG trends & circadian activity…

ByRidhi RastogiJune 1, 2026

NEWS

Eli Lilly Highlights P-III (LIBRETTO-432) Trial Data on Retevmo for Early-Stage RET Fusion–Positive NSCLC at ASCO 2026

Shots: Lilly's global P-III (LIBRETTO-432) trial assessed Retevmo (selpercatinib; 160mg, BID) vs PBO in 151 pts with early-stage (IB-IIIA) RET fusion-positive NSCLC following completion of definitive radiotherapy or surgery with curative intent, & other adjuvant therapy Trial met the 1EP, improving the EFS by 83% in stage II–IIIA RET-positive NSCLC (n=109), with 24mos. EFS rates of…

ByRidhi RastogiJune 1, 2026

NEWS

Akeso Presents the P-III (HARMONi-6) Trial Data on Ivonescimab + CT in 1L Squamous NSCLC at ASCO 2026

Shots: The Akeso's global P-III (HARMONi-6/AK112-306) trial assessed ivonescimab + CT vs Tevimbra + CT to treat pts (n=532) with 1L sqNSCLC, meeting its 2EP of improved OS As of Feb 27, 2026 (mFU: 21.36mos.), ivonescimab + CT reduced the death risk by 34%(mOS: 27.9 vs 23.7mos.), with 12 and 24mos. OS rate of 78.9%…

ByRidhi RastogiJune 1, 2026

Ridhi Rastogi

AbbVie’s Aquipta Receives EC Approval for Acute Migraine Treatment

Rallybio to Merge with Avenzo Therapeutics to Advance Next-Generation Oncology Therapies

Amgen Reports the EC Approval of Imdylltra to Treat ES-SCLC

Servier to Acquire Edgewise Therapeutics’ Muscular Dystrophy Business for ~$2.65B

Haisco Enters ~$3.05B License and Research Collaboration with Lilly to Develop Novel Medicines Across Multiple Therapeutic Areas

Revolution Medicines Highlights P-III (RASolute 302) Trial Results on Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer

Agios Pharmaceuticals Licenses Cevidoplenib from Oscotec in a ~$165M Deal

NeuroPace Receives the US FDA Approval for ECoG Assistant to Advance AI-Driven Epilepsy Care

Eli Lilly Highlights P-III (LIBRETTO-432) Trial Data on Retevmo for Early-Stage RET Fusion–Positive NSCLC at ASCO 2026

Akeso Presents the P-III (HARMONi-6) Trial Data on Ivonescimab + CT in 1L Squamous NSCLC at ASCO 2026

Contact US

FOLLOW US